David Hutton

New World Medical notes that the intuitively designed Streamline features ClickPulse technology that targets the eye’s conventional outflow pathway.

The companies note that the partnership will propel Ray Therapeutics’ lead optogenetics gene therapy to Phase 1-2 clinical trials.

The eye care nonprofit has continually harnessed the power of innovation to reach new heights in the fight against avoidable blindness.

The group is offering free sight-savings resources to employees and their employers.

According to the U.S. Department of Health and Human Services, nearly $19 billion in total aid has been distributed to providers since November.

The company expects to have topline proof of concept data by the end of the first quarter of the year.

Dr. Raymond Douglas discusses the real-world adherence to teprotumumab as a treatment for thyroid eye disease.

TearSolutions Inc. is preparing to conduct two trials, one in a primary Sjögren’s Syndrome patient population and the second in a potentially less severe general dry eye population for the treatment of DED.

The organization uses its Eyes on Capitol Hill program to educate lawmakers and their staff on a variety of vision health issues, including vision health inequities, the need for improved vision surveillance, the impact of community eye health programs, and disparities in access to affordable eyecare services.

Dr. Quan Dong Nguyen reviews a Monte Carlo simulation that showed evidence that treating severe NPDR with anti-VEGF therapy garners positive results.

KSI-301, a therapy for patients with nAMD, did not meet the primary endpoint of showing non-inferior visual acuity gains compared to aflibercept given every eight weeks, however it was safe and well tolerated with no new or unexpected safety signals.

In this episode of EyePod, Ora Clinical’s Keith Lane offers a brief overview of the current state of ophthalmology and its standardized endpoints. He also discusses some of the challenges that gene therapy has faced, particularly in relation to ophthalmology. He also offers his outlook for the future of gene therapy.

The company will use proceeds from the Series A to assemble and develop a diversified pipeline of product candidates that combines scientifically compelling targets with innovative translational approaches.

The company is revealing the 8-year follow up results of its novel Elios Excimer Laser Trabeculostomy procedure combined with cataract surgery.

While there is currently no cure for blindness, an artificial vision system has undergone its first successful implantation, bringing with it the potential to restore partial vision to people who have lost their sight.

The NGF0121 study will enroll 100 patients and will use Schirmer's test and the Symptom Assessment Questionnaire in Dry Eye questionnaire as its co-primary endpoints to measure improvement in signs and symptoms of dry eye over time.

Results from the study were presented by Russell Tait, PhD, CEO of PolyActiva, at the Glaucoma 360 New Horizons Forum in San Francisco, California

At Angiogenesis, Dr. David Brown presented the Phase 2 results of the CANDELA study for high dose aflibercept 8 milligram for wet AMD; here, he discusses those results.

The company recently took the wraps off an exclusive agreement with the Medical University of South Carolina (MUSC) Foundation for Research Development to license next generation complement-targeted gene therapies for the treatment of geographic atrophy and other ocular diseases.

Kato Pharmaceuticals will study the efficacy of Resolv ER for the treatment of vitreomacular attachment.

According to data presented by Horizon Therapeutics at the North American Neuro-Ophthalmology Society annual meeting held this week in Austin, Texas, Uplizna treatment is linked to fewer severe attacks and reduced levels of key disease-related biomarkers versus placebo.

Researchers know that parts of the retina are considered as biomarkers for Alzheimer’s, but the team from Otago’s Dunedin Multidisciplinary Health and Development Research Unit in New Zealand have been investigating the retina’s potential to indicate cognitive change earlier in life.

According to the company, it is developing elamipretide for treatment of extra-foveal GA under U.S. FDA Fast Track designation.

AM712 is a novel bispecific biologic molecule specifically designed for ocular use. In pre-clinical studies, it demonstrated efficacy, ocular pharmacokinetics, and the desired safety profile supporting clinical exploration.

During a presentation at the Bascom Palmer Eye Institute Angiogenesis, Exudation, and Degeneration 2022 conference, Robert Bhisitkul, MD, PhD, provided 24-week clinical data from the Phase 1 study, demonstrating that patients with DME and wAMD showed improved visual acuity through 24 weeks following a single dose of UBX1325.

Robert L. Stamper, MD, speaks with Ophthalmology Times®' David Hutton on intraocular pressure measurement, corneal elasticity, and why hysteresis is important for glaucoma management.

This year's Shaffer-Hetherington-Hoskins Lecture keynote speaker Joseph Caprioli, MD, focuses on the phenotypes of primary open-angle glaucoma with Ophthalmology Times®' David Hutton at Glaucoma 360.

Dr. Carl Regillo discusses the 100-week results of KESTREL and KITE, two pivotal Phase 3 studies for brolucizumab for the treatment of diabetic macular edema.

Dr. Arshad M. Khanani reviews the Phase 2 part A results of the KALAHARI study of THR-149 for the treatment of DME.